At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELDN Eledon Pharmaceuticals, Inc.
Pre-Market Trading 06-10 06:44:30 EDT
2.78
+0.06
+2.21%
High2.84
Low2.71
Vol117.14K
Open2.74
D1 Closing2.72
Amplitude4.78%
Mkt Cap107.05M
Tradable Cap86.54M
Total Shares38.51M
T/O324.49K
T/O Rate0.38%
Tradable Shares31.13M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Eledon Pharmaceuticals (ELDN) and Abbott Laboratories (ABT)
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.